Literature DB >> 33822817

The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD).

Roberta D'Ambrosio1, Irene Campi2, Marco Maggioni3, Riccardo Perbellini1, Enza Giammona4, Roberta Stucchi4, Marta Borghi1, Elisabetta Degasperi1, Annalisa De Silvestri5, Luca Persani2,6, Laura Fugazzola2,7, Pietro Lampertico1,7.   

Abstract

BACKGROUND: Data on the role of hypothyroidism in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis are conflicting, although selective Thyroid Hormone Receptor (THR)-β agonists have been identified as potential therapy in patients with non-alcoholic steatohepatitis (NASH). Therefore, we investigated the association between hypothyroidism and NAFLD histological features potentially associated with progressive liver disease.
METHODS: Between 2014 and 2016, consecutive patients with histologically proven NAFLD and frozen serum available for thyroid function tests assessment were included. NAFLD was staged according to the NAFLD Activity Score (NAS), and fibrosis according to Kleiner. NASH was defined as NAS ≥4, significant fibrosis as F2-F4 and significant steatosis as S2-S3. Thyroid function tests (TFT; TSH, FT3, FT4, rT3), TPO-Ab and Tg-Ab were also assessed.
RESULTS: Fifty-two patients were analyzed: median age 54 years, 58% females, LSM 7.8 kPa, 27% diabetics, 14% hypothyroid. At histology, NASH was present in 21 (40%), F2-F4 in 28 (54%) and S2-S3 in 30 (58%) patients. Rates of hypothyroidism were similar independently of the presence of NASH (p = 0.11), significant fibrosis (p = 0.21) or steatosis (p = 0.75). However, hypothyroid patients displayed a higher NAS (p = 0.02) and NASH (p = 0.06) prevalence. At multivariate analysis, TFT were not independently associated with histology.
CONCLUSION: Hypothyroidism was highly prevalent in NAFLD patients, and was associated with increased NAFLD activity, but not with fibrosis and steatosis severity. Thus, thyroid dysfunction might play a direct and/or indirect in the pathogenesis of NAFLD and NASH.

Entities:  

Year:  2021        PMID: 33822817     DOI: 10.1371/journal.pone.0249614

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  6 in total

1.  The protective effect of hesperidin on the liver of hypothyroid rats mediated by nuclear factor erythroid 2-related factor 2-dependent activation of heme oxygenase 1.

Authors:  Walaa Hegazy; Adel Abdel-Moneim; Eman S Abdel-Rehiem; Marwa Salah; Manal Abdul-Hamid
Journal:  J Mol Histol       Date:  2022-02-28       Impact factor: 2.611

Review 2.  Targeting Thyroid Hormone/Thyroid Hormone Receptor Axis: An Attractive Therapy Strategy in Liver Diseases.

Authors:  Qianyu Tang; Min Zeng; Linxi Chen; Nian Fu
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

Review 3.  Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD.

Authors:  Maria Mavromati; François R Jornayvaz
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

Review 4.  The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications.

Authors:  Rossella Palma; Annamaria Pronio; Mario Romeo; Flavia Scognamiglio; Lorenzo Ventriglia; Vittorio Maria Ormando; Antonietta Lamazza; Stefano Pontone; Alessandro Federico; Marcello Dallio
Journal:  J Clin Med       Date:  2022-06-24       Impact factor: 4.964

Review 5.  Influence of Altered Thyroid Hormone Mechanisms in the Progression of Metabolic Dysfunction Associated with Fatty Liver Disease (MAFLD): A Systematic Review.

Authors:  Rafael Aguiar Marschner; Fernanda Arenhardt; Rafael Teixeira Ribeiro; Simone Magagnin Wajner
Journal:  Metabolites       Date:  2022-07-22

Review 6.  Hypothyroidism and Diabetes-Related Dementia: Focused on Neuronal Dysfunction, Insulin Resistance, and Dyslipidemia.

Authors:  Hee Kyung Kim; Juhyun Song
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.